| Primary |
| Hypertension |
50.0% |
| Arrhythmia Prophylaxis |
12.5% |
| Cardiac Failure |
12.5% |
| Hypercholesterolaemia |
12.5% |
| Type 2 Diabetes Mellitus |
12.5% |
|
|
| Secondary |
| Hypertension |
33.3% |
| Cardiac Failure |
10.8% |
| Renal Impairment |
6.7% |
| Coronary Artery Disease |
6.4% |
| Atrial Fibrillation |
5.9% |
| Tachyarrhythmia |
4.9% |
| Prophylaxis |
4.4% |
| Type 2 Diabetes Mellitus |
3.9% |
| Sleep Disorder |
3.0% |
| Product Used For Unknown Indication |
2.7% |
| Drug Use For Unknown Indication |
2.5% |
| Pain |
2.5% |
| Hyperuricaemia |
2.2% |
| Depression |
2.0% |
| Dyspepsia |
2.0% |
| Cardiac Failure Acute |
1.5% |
| Cardiac Failure Chronic |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.5% |
| Epilepsy |
1.2% |
| Hyperparathyroidism |
1.2% |
|
| Bradyarrhythmia |
11.3% |
| Hyperkalaemia |
9.4% |
| Renal Failure Acute |
9.4% |
| Hypotension |
7.5% |
| Nausea |
7.5% |
| Therapeutic Agent Toxicity |
7.5% |
| Rhabdomyolysis |
5.7% |
| Bradycardia |
3.8% |
| General Physical Health Deterioration |
3.8% |
| Heart Rate Decreased |
3.8% |
| Prothrombin Time Abnormal |
3.8% |
| Pulmonary Hypertension |
3.8% |
| Syncope |
3.8% |
| Tachyarrhythmia |
3.8% |
| Torsade De Pointes |
3.8% |
| Type 2 Diabetes Mellitus |
3.8% |
| Ejection Fraction Decreased |
1.9% |
| Hypertension |
1.9% |
| Hypertensive Crisis |
1.9% |
| Hypoxic-ischaemic Encephalopathy |
1.9% |
|
| Concomitant |
| Hypertension |
21.6% |
| Product Used For Unknown Indication |
14.4% |
| Atrial Fibrillation |
11.1% |
| Cardiac Failure |
6.7% |
| Drug Use For Unknown Indication |
5.7% |
| Pain |
5.0% |
| Type 2 Diabetes Mellitus |
4.1% |
| B-cell Lymphoma |
3.8% |
| Coronary Artery Disease |
3.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.2% |
| Tachyarrhythmia |
3.1% |
| Rheumatoid Arthritis |
2.9% |
| Prophylaxis |
2.4% |
| Hyperlipidaemia |
2.3% |
| Diabetes Mellitus |
2.2% |
| Pneumonia |
2.1% |
| Thrombosis Prophylaxis |
1.6% |
| Osteoporosis |
1.5% |
| Urinary Tract Infection |
1.4% |
| Renal Transplant |
1.4% |
|
| Renal Failure Acute |
17.1% |
| Transaminases Increased |
8.3% |
| Drug Interaction |
7.9% |
| Clostridium Difficile Colitis |
6.9% |
| Pyrexia |
6.5% |
| Weight Decreased |
6.0% |
| Vomiting |
5.6% |
| Syncope |
4.6% |
| Renal Failure |
4.2% |
| Gastrointestinal Haemorrhage |
3.7% |
| Wrong Technique In Drug Usage Process |
3.7% |
| Gamma-glutamyltransferase Increased |
3.2% |
| Hypoglycaemia |
3.2% |
| Septic Shock |
3.2% |
| Thrombocytopenia |
3.2% |
| Myocardial Infarction |
2.8% |
| Pneumonia |
2.8% |
| Dehydration |
2.3% |
| Hepatic Encephalopathy |
2.3% |
| Somnolence |
2.3% |
|
| Interacting |
| Hypertension |
18.8% |
| Atrial Fibrillation |
12.9% |
| Rheumatoid Arthritis |
11.8% |
| Bronchitis |
11.2% |
| Product Used For Unknown Indication |
10.6% |
| Osteoporosis |
7.1% |
| Type 2 Diabetes Mellitus |
4.7% |
| Coronary Artery Disease |
3.5% |
| Thyroid Function Test Abnormal |
3.5% |
| Drug Use For Unknown Indication |
2.4% |
| Cardiac Failure |
1.8% |
| Prophylaxis |
1.8% |
| Tachyarrhythmia |
1.8% |
| Acidosis |
1.2% |
| Cardiovascular Event Prophylaxis |
1.2% |
| Glaucoma |
1.2% |
| Gout |
1.2% |
| Hyperlipidaemia |
1.2% |
| Hyperuricaemia |
1.2% |
| Ischaemic Heart Disease Prophylaxis |
1.2% |
|
| Therapeutic Agent Toxicity |
25.0% |
| Drug Interaction |
20.0% |
| Renal Failure Acute |
20.0% |
| Torsade De Pointes |
10.0% |
| Pulmonary Embolism |
5.0% |
| Renal Failure Chronic |
5.0% |
| Sinus Bradycardia |
5.0% |
| Urinary Retention |
5.0% |
| Weight Decreased |
5.0% |
|
